Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 194 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2015', provides an overview of the Gastrointestinal Stromal Tumor (GIST)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastrointestinal Stromal Tumor (GIST) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Gastrointestinal Stromal Tumor (GIST) Overview 9
Therapeutics Development 10
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview 10
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis 11
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies 12
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes 14
Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies 18
Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes 20
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 21
AB Science 21
Advenchen Laboratories, LLC 22
Ariad Pharmaceuticals, Inc. 23
Array BioPharma Inc. 24
Astex Pharmaceuticals, Inc. 25
Blueprint Medicines 26
Boston Biomedical, Inc. 27
Chipscreen Biosciences Ltd 28
Daiichi Sankyo Company, Limited 29
Deciphera Pharmaceuticals, LLC 30
F. Hoffmann-La Roche Ltd. 31
GlaxoSmithKline plc 32
Jiangsu Hengrui Medicine Co., Ltd. 33
Natco Pharma Limited 34
Nerviano Medical Sciences S.r.l. 35
Novartis AG 36
Otsuka Holdings Co., Ltd. 37
Plexxikon Inc. 38
Synta Pharmaceuticals Corp. 39
Takeda Pharmaceutical Company Limited 40
Threshold Pharmaceuticals, Inc. 41
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Mechanism of Action 47
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
alpelisib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
apatinib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BBI-503 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
binimetinib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BLU-285 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
buparlisib hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
crenolanib besylate - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CS-2164 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
DCC-2618 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
evofosfamide - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ganetespib - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
LOP-628 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
masitinib - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
motesanib diphosphate - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
nilotinib - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
NMSP-088 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
NRCAN-019 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
onalespib - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
OPB-51602 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
pazopanib hydrochloride - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
PLX-3397 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
ponatinib hydrochloride - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
quizartinib dihydrochloride - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
SF-1126 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
SHR-1020 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
vemurafenib - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Gastrointestinal Stromal Tumor (GIST) - Recent Pipeline Updates 129
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 182
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 183
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 184
Featured News & Press Releases 184
Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets 184
Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting 185
Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors 185
Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican 186
Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig 187
Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors 188
Jun 02, 2013: Threshold Pharma Announces Data From Two Ongoing Phase I/II Trials Of TH-302 At 2013 ASCO Annual Meeting 189
Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors 191
Mar 20, 2013: Ariad Pharma Announces Presentations Of Preclinical Data On Iclusig At AACR Annual Meeting 191
Oct 04, 2012: AB Science Announces Acceptance Of Marketing Application For Masitinib By EMA To Treat Gleevec-resistant Gastro-intestinal Stromal Tumor 191
Appendix 193
Methodology 193
Coverage 193
Secondary Research 193
Primary Research 193
Expert Panel Validation 193
Contact Us 193
Disclaimer 194

List of Tables

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2015 10
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Development by Companies, H1 2015 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science, H1 2015 21
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories, LLC, H1 2015 22
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 23
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc., H1 2015 24
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 25
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines, H1 2015 26
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical, Inc., H1 2015 27
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2015 28
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 29
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 30
Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 31
Gastrointestinal Stromal Tumor (GIST) - Pipeline by GlaxoSmithKline plc, H1 2015 32
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 33
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Limited, H1 2015 34
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 35
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2015 36
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 37
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc., H1 2015 38
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Synta Pharmaceuticals Corp., H1 2015 39
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 40
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 41
Assessment by Monotherapy Products, H1 2015 42
Assessment by Combination Products, H1 2015 43
Number of Products by Stage and Target, H1 2015 45
Number of Products by Stage and Mechanism of Action, H1 2015 48
Number of Products by Stage and Route of Administration, H1 2015 51
Number of Products by Stage and Molecule Type, H1 2015 53
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Recent Pipeline Updates, H1 2015 129
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2015 182
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2015 183